<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aspirin for the secondary prevention of atherosclerotic cardiovascular disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aspirin for the secondary prevention of atherosclerotic cardiovascular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Aspirin for the secondary prevention of atherosclerotic cardiovascular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles H Hennekens, MD, FACPM, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joann G Elmore, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Freek Verheugt, MD, FACC, FESC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3335700291"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atherosclerotic cardiovascular disease (CVD), which includes coronary artery disease, cerebrovascular disease, and peripheral artery disease, is the leading cause of death in the United States and most developed countries and is rapidly becoming the leading cause of death in the world. In 2014, in the United States alone, CVD caused more than 900,000 deaths. The totality of evidence from basic research, clinical investigations, observational epidemiologic studies, and randomized trials has provided strong support for the net benefits of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in secondary prevention of CVD events [<a href="#rid1">1</a>].</p><p>The following groups of patients with established cardiovascular disease, or at high risk, benefit from <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for the prevention of new cardiovascular events:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with acute coronary artery syndromes such as acute myocardial infarction (MI) and unstable angina.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with acute occlusive stroke.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stable CVD, such as those with chronic coronary syndrome, also referred to as stable ischemic heart disease (including those who have undergone revascularization with coronary artery bypass graft surgery); stable peripheral artery disease; or carotid artery disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have undergone coronary artery stenting.</p><p></p><p>The evidence supporting the efficacy of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for secondary prevention of atherosclerotic CVD events will be reviewed here. The use of aspirin in primary prevention of CVD and cancer is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p>The potential benefits of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in patients with non-atherosclerotic CVD, such as heart failure, atrial fibrillation, or venous thromboembolic disease, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure", section on 'Effect of aspirin'</a> and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p>Other relevant topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/1554.html" rel="external">"Coronary artery bypass graft surgery: Graft choices"</a> and  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a>.)</p><p></p><p></p><p class="headingAnchor" id="H2087337823"><span class="h1">MECHANISMS OF ACTION</span><span class="headingEndMark"> — </span>This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Mechanisms of action'</a>.)</p><p class="headingAnchor" id="H1019438951"><span class="h1">EFFICACY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> produces statistically significant and clinically important reductions in the risk of subsequent myocardial infarction (MI), stroke, and vascular death among a wide range of patients who have survived an occlusive cardiovascular disease (CVD) event [<a href="#rid2">2,3</a>].</p><p>The benefits of long-term <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy in secondary prevention were suggested in individual randomized trials as well as conclusively demonstrated in a series of meta-analyses of randomized trials by the Antiplatelet Trialists’ Collaboration (which later changed its name to the Antithrombotic Trialists' Collaboration). A 2002 meta-analysis included individual patient data from 195 randomized trials of antiplatelet therapy, principally with aspirin, among more than 135,000 high-risk patients with prior evidence of CVD, including prior or acute MI, prior or acute stroke or transient ischemia attacks (TIA), and other high-risk groups such as those with unstable angina, stable angina, peripheral artery disease, coronary artery bypass graft surgery, percutaneous coronary intervention, atrial fibrillation, and valvular disease [<a href="#rid2">2</a>].</p><p>The major conclusions were as follows  (<a class="graphic graphic_table graphicRef56243" href="/z/d/graphic/56243.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Antiplatelet therapy, primarily with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, significantly reduced the risk of subsequent vascular events (nonfatal MI, nonfatal stroke, and vascular death) by approximately 22 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In absolute terms, antiplatelet therapy led to avoidance of approximately 36 vascular events per 1000 patients with a prior MI treated for a mean of 27 months, 38 events per 1000 patients with an acute MI treated for one month, 36 events per 1000 patients with a previous stroke or TIA treated for 29 months, 9 events per 1000 patients with an acute stroke treated for 0.7 months, and 22 events per 1000 patients with other high-risk features treated for 22 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There were no significant differences in efficacy or safety between doses of 75 to 150 mg/day (called low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) and 160 to 325 mg/day (called medium-dose aspirin).</p><p></p><p class="headingAnchor" id="H157746698"><span class="h2">Dose</span><span class="headingEndMark"> — </span>The optimal daily dose of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for long-term, secondary prevention of CVD events is unclear. Most of our contributors prescribe 75 to 100 mg/day. Some experts use higher doses, especially in individuals with overweight or obesity. The potential interrelationships of dose, body weight, and outcomes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin", section on 'Body weight'</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> in a dose range from 75 to 325 mg/day has been evaluated in numerous trials and their meta-analyses. In their meta-analysis of those trials, the Antithrombotic Trialists' Collaboration found that benefits were similar at all doses of aspirin from 75 to 1300 mg/day [<a href="#rid2">2</a>]. By contrast, the risk of bleeding began to increase with doses above 325 mg/day.</p><p>In the open-label ADAPTABLE trial, 15,076 patients with ASCVD were randomly assigned to receive either 81 or 325 mg of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> daily for a median follow-up of 26 months. The primary prespecified composite outcome of all-cause mortality, hospitalization for myocardial infarction, or hospitalization for stroke was comparable between those randomized to 81 mg (7.51 percent) or 325 mg (7.28 percent), yielding a hazard ratio of 1.02 (95% CI 0.91-1.14) [<a href="#rid4">4</a>]. Rates of hospitalization for major bleeding were also comparable. Those randomized to 325 mg were more likely to switch to 81 mg than vice versa (41.6 versus 7.1 percent). In addition, aspirin discontinuation rates were higher in the 325 than 81 mg dose (9 versus 7 percent). It is plausible that these differences would lead to underestimation of the true benefits as well as risks of the 325 mg dose.</p><p>The safety of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> with regard to bleeding, especially gastrointestinal bleeding, has been well studied, but interpretations of the available data differ. Some experts refer to the available direct comparisons from randomized trials to suggest safety equivalence across the dose range of 75 to 325 mg/day, while others refer to subgroup analyses and some observational and claims data to suggest a lower rate of bleeding at the lower end of the dose range.</p><p>In addition to direct randomized comparisons, there are indirect randomized comparisons as well as the even less reliable nonrandomized comparisons. In indirect and nonrandomized comparisons, higher doses may be prescribed to sicker patients, leading to more adverse clinical CVD outcomes due to confounding by indication [<a href="#rid2">2,5-7</a>]. In a post hoc subgroup analysis from the CHARISMA trial [<a href="#rid8">8</a>], there was no difference in efficacy between doses of 75 to 150 mg/day (called low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) and 160 to 325 mg/day (called medium-dose aspirin), as the proportional reductions in clinical CVD events were 32 and 26 percent, respectively. There were also no apparently greater clinical benefits in patients given higher doses up to 1500 mg/day.</p><p>In theory, it is also plausible that lower doses of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> might be more effective than higher doses because such low doses "spare" prostacyclin (a platelet antiaggregant and vasodilator) and cause less bleeding. In practice, however, the clinical relevance of prostacyclin sparing has never been demonstrated. With respect to efficacy, based on small numbers of events in three randomized trials, doses below 75 mg/day showed a nonsignificant benefit of about 13 percent, which was about one-half the significant overall benefit of about 25 percent seen with higher doses up to 1500 mg/day [<a href="#rid2">2</a>].</p><p>In patients with onset of acute occlusive CVD events, a loading dose of at least 162 mg of regular <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> but preferably 325 mg should be given to achieve a rapid clinical antithrombotic effect. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a>.)</p><p class="headingAnchor" id="H3240417772"><span class="h2">Formulation</span><span class="headingEndMark"> — </span>The formulation of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (regular or enteric coated) should be an individual clinical decision made with each patient. Enteric-coated aspirin is designed to resist disintegration in the stomach; thus, health care providers and their patients may believe this to be an attractive alternative to conventional aspirin. Although this preparation may reduce erosions on endoscopy, enteric coating does not appear to protect against the clinically relevant endpoint of gastrointestinal bleeding [<a href="#rid9">9</a>]. This finding is not surprising, since injury severe enough to induce bleeding is likely to reflect systemic as well as local effects of aspirin. (See  <a class="medical medical_review" href="/z/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a> and  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity", section on 'Enteric-coated and buffered aspirin'</a>.)</p><p>In some [<a href="#rid10">10</a>] but not all [<a href="#rid11">11,12</a>] studies, equivalent doses of enteric-coated <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are not as effective as plain aspirin. Lower bio-availability of these preparations and poor absorption from the higher pH environment of the small intestine may result in inadequate platelet inhibition, particularly in heavier subjects. These data contribute to the formulation of the hypothesis that low-dose, enteric-coated aspirin does not produce adequate platelet inhibition.</p><p>In acute occlusive CVD events such as acute coronary syndrome or stroke, regular <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be used to achieve a rapid clinical antithrombotic effect. If the only available preparation is enteric coated, the single tablet or multiple tablets necessary to achieve the recommended dose of 325 mg should be crushed or chewed.</p><p class="headingAnchor" id="H2246914816"><span class="h1">ALTERNATIVES TO ASPIRIN</span><span class="headingEndMark"> — </span>In patients who are unable to take <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, or those with a history of gastrointestinal bleeding, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is a reasonable alternative.</p><p>Some evidence from randomized trials suggests that <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> may be have somewhat greater efficacy than <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, a finding which should be weighed against much higher costs and greater likelihood of side effects. In this regard, clopidogrel seems to have a better safety profile than ticlopidine.</p><p>In the CAPRIE trial of 19,185 patients with a recent myocardial infarction (MI), stroke, or peripheral artery disease, those assigned to <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> had a modest and marginally significant incremental benefit compared with those assigned to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in the prevention of stroke, MI, and vascular disease (annual event rates 5.3 versus 5.8 percent) [<a href="#rid13">13</a>].</p><p>A small but significant reduction in serious cardiovascular events was also noted with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> compared with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in the Antithrombotic Trialists' Collaboration (10.1 versus 11.1 percent) [<a href="#rid2">2</a>] and with <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> or clopidogrel compared with aspirin in a meta-analysis of four trials that included 22,656 patients at high risk for vascular disease (12 versus 13 percent at approximately two years, odds ratio [OR] 0.91) [<a href="#rid14">14</a>].</p><p>In the latter report, <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> were associated with lower incidences of gastrointestinal hemorrhage and upper-gastrointestinal upset but with a higher incidence of rash, diarrhea, and, with ticlopidine, neutropenia [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1016966315"><span class="h1">BLEEDING</span><span class="headingEndMark"> — </span>The primary safety concern with the chronic use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is major bleeding, chiefly from the gastrointestinal tract. In randomized comparisons against placebo, 325 mg/day of aspirin when used for five years leads to about a 1 percent absolute increase in risk of major gastrointestinal bleeding [<a href="#rid15">15,16</a>]. Further, there is a very small absolute increased risk of cerebral hemorrhage is about one event per 1000 patients treated for five years. Since these absolute increases in risk are far less than the absolute decrease in the risk of subsequent myocardial infarction (MI), stroke, and vascular death among a wide range of patients who have survived an occlusive cardiovascular disease (CVD) event, most secondary prevention patients should be prescribed aspirin for long-term use. (See <a class="local">'Efficacy'</a> above and  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H371279451"><span class="h1">CESSATION OF ASPIRIN FOR SURGERY OR PROCEDURES</span><span class="headingEndMark"> — </span>The most plausible and proven benefits of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are acute and likely result from irreversible inhibition of cyclooxygenase in platelets whose half-life is about eight days. Thus, even after one week of cessation, the beneficial effects of aspirin are no longer apparent. Therefore, after a short time, cessation of aspirin may increase risks of complications such as myocardial infarction (MI), stroke, or stent thrombosis. The major reasons for clinician-directed cessation of aspirin therapy have been minor surgery, endoscopy, and dental treatment. It is also important to note that aspirin may need to be continued in patients at high risk for perioperative occlusive vascular complications (eg, those undergoing coronary artery bypass graft or peripheral arterial surgery). This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a> and  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Aspirin'</a>.)</p><p class="headingAnchor" id="H1170223028"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H4047693720"><span class="h2">Anticoagulated patients</span><span class="headingEndMark"> — </span>For patients with stable cardiovascular disease (CVD) or at high risk who are anticoagulated, we do not routinely add <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. We believe that any further reductions in occlusion are offset by increased risks of major bleeding. However, some studies suggest concomitant use with coumadin or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>.</p><p>Many patients with CVD receiving <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> also need initiation of long-term oral anticoagulant or novel antiplatelet therapy for diagnoses such as atrial fibrillation. Conversely, many patients who are receiving long-term anticoagulant or novel antiplatelet therapy may develop an indication for aspirin. It has been estimated that between 5 and 10 percent of patients scheduled for percutaneous coronary intervention are taking oral anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Introduction'</a>.)</p><p>For patients who have an indication for both antithrombotic interventions, it is important to know the absolute benefit on clinical CVD outcomes, the risk of major bleeding, and whether the addition of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> significantly improves outcomes (reduction in the risk of adverse ischemic cardiovascular events), since the risk of major bleeding increases significantly when both agents are used compared with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> alone. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Introduction'</a>.)</p><p>In patients with stable CVD, the addition of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> to oral anticoagulants offers some protection against CVD events, but the risk of major bleeding is significantly increased compared with oral anticoagulant use alone.</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2003 meta-analysis of patients with established CVD, three trials (over 3000 patients) compared moderate- with high-intensity <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (international normalized ratio [INR] &gt;2) plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> with warfarin alone [<a href="#rid17">17</a>]. Combined therapy was associated with a nonsignificant lowering of the rate of cardiovascular death, myocardial infarction (MI), and stroke (12.5 versus 14.3 percent, respectively; odds ratio [OR] 0.86, 95% CI 0.70-1.06). The interpretation of these data should also be viewed in the context that the achieved INR target of 2.5 was somewhat lower than sometimes recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indirect evidence suggesting benefit from oral anticoagulation derives from the APRICOT-2 trial, not included in the meta-analysis, in which 308 patients with ST-elevation MI who underwent fibrinolytic therapy were randomly assigned to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or to aspirin with moderate-intensity anticoagulation (INR 2 to 3) with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid18">18</a>]. At three-month follow-up, the rate of reocclusion was significantly lower in those assigned to both drugs (15 versus 28 percent; relative risk [RR] 0.46, 96% CI 0.21-0.89).</p><p></p><p class="headingAnchor" id="H1295262130"><span class="h2">Aspirin nonresponse and resistance</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> nonresponse and resistance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin", section on 'Management of treatment failure'</a>.)</p><p class="headingAnchor" id="H2462681595"><span class="h2">Aspirin sensitivity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> sensitivity is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Aspirin sensitivity'</a>.)</p><p class="headingAnchor" id="H1483888836"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>All major societal guidelines recommend <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for secondary prevention in patients with established cardiovascular disease [<a href="#rid19">19-21</a>].</p><p class="headingAnchor" id="H3017565407"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115645.html" rel="external">"Society guideline links: Secondary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H3897144338"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3428.html" rel="external">"Patient education: Aspirin in the primary prevention of cardiovascular disease and cancer (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H3090881010"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> produces clinically important and statistically significant reductions in the risk of subsequent myocardial infarction (MI), stroke, and vascular death among a wide range of patients who have survived an occlusive cardiovascular disease (CVD) event. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> produces increased risks of major bleeding, particularly from the gastrointestinal tract that are small in relation to the far larger benefits on occlusive vascular events. The use of higher doses above 325 mg/day is associated with higher risks of bleeding. (See <a class="local">'Bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with established and stable CVD or those at high risk, we recommend long-term <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). We give 75 to 100 mg/day. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1">In patients who are unable to take <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, or those with a history of gastrointestinal bleeding, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is a reasonable alternative. (See <a class="local">'Alternatives to aspirin'</a> above.)</p><p></p><p class="bulletIndent1">We suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> rather than <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> for secondary prevention (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with either established CVD or at high risk who have an indication for long-term oral anticoagulant or novel therapy, we suggest not adding <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> to reduce the risk of cardiovascular events due to the increased risk of bleeding (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Anticoagulated patients'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2751.</a></li><li><a class="nounderline abstract_t">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.</a></li><li><a class="nounderline abstract_t">Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121:43.</a></li><li><a class="nounderline abstract_t">Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med 2021; 384:1981.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Sechenova O, Hollar D, Serebruany VL. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther 2006; 11:170.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80:749.</a></li><li><a class="nounderline abstract_t">Johnson ES, Lanes SF, Wentworth CE 3rd, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159:1248.</a></li><li><a class="nounderline abstract_t">Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009; 150:379.</a></li><li><a class="nounderline abstract_t">Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413.</a></li><li><a class="nounderline abstract_t">Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37:2153.</a></li><li><a class="nounderline abstract_t">Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46:1258.</a></li><li><a class="nounderline abstract_t">Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006; 151:976.e7.</a></li><li><a class="nounderline abstract_t">CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.</a></li><li><a class="nounderline abstract_t">Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31:1779.</a></li><li><a class="nounderline abstract_t">Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321:1183.</a></li><li><a class="nounderline abstract_t">Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162:2197.</a></li><li><a class="nounderline abstract_t">Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:62S.</a></li><li><a class="nounderline abstract_t">Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002; 106:659.</a></li><li><a class="nounderline abstract_t">Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.</a></li><li><a class="nounderline abstract_t">Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124:2458.</a></li><li><a class="nounderline abstract_t">Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635.</a></li></ol></div><div id="topicVersionRevision">Topic 110006 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9355934" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786451" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187072" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33999548" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17056829" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2676237" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371234" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A metaregression analysis of the dose-response effect of aspirin on stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293071" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937281" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794200" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198840" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16644316" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918275" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884487" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073508" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390062" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644343" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oral anticoagulants in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12163424" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052934" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22555213" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
